Punjab Chemicals & Crop Protection Ltd
PUNJABCHEMPunjab Chemicals & Crop Protection Ltd's earnings have outrun its stock. EPS grew +64.3% in a year against a −17.6% price move.
The sharpest disagreement: annual EPS moved +64.3% against a −17.6% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (26 weeks in) while the P/E sits at the 21st percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +4.8% year on year, and 90% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Punjab Chemicals & Crop Protection Ltd trades at ₹1,144, in a downtrend and 26 weeks into that stage. That is +3.3% against its own 200-day average. It sits at 40% of a 52-week range of ₹909 to ₹1,493. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 4 straight weeks.
Today the stock is in a downtrend — week 26 of stage 4, confirmed. At ₹1,144 it trades +3.3% versus its 200-day average and sits at 40% of its 52-week range (₹909–₹1,493).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +784% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 4 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Punjab Chemicals & Crop Protection Ltd trades at 21.0× P/E, near the bottom of its own range — cheaper only 21% of the time. Its long-run median P/E is 29.3×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 21.0× is near the bottom of its own range — cheaper only 21% of the time, against a long-run median of 29.3× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +64.3% against a −17.6% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the −3.9%/yr price move, ~+6.5%/yr came from earnings growth and ~−10.4 pp from the multiple (compressing); over 10y, of the +18.8%/yr price move, ~+26.9%/yr came from earnings growth and ~−8.1 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Punjab Chemicals & Crop Protection Ltd reads as improving on its fundamental arc. Improving — profit growth bottomed 7 quarters ago at −39.7% and has held its recovery at +43.5%, ROCE holding at 19.0%. The read is built from 8 quarters across 4 curves, on partial evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +14.3% | +0.8% | +8.7% | +6.7% |
| Profit | +64.1% | +1.6% | +5.5% | +17.3% |
| EPS | +64.3% | +1.5% | +5.4% | +17.0% |
| Share price | −17.6% | +10.5% | −3.9% | +18.8% |
4-Factor Sector Score
61.8/100 — rank 3 of 24 in Pesticides/Agrochemicals · 81% evidence confidence
Punjab Chemicals & Crop Protection Ltd scores 61.8 out of 100 against the 24 companies it is compared with in Pesticides/Agrochemicals, ranking 3. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 22.7 + 18.3 + 12.1 + 8.7 = 61.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Punjab Chemicals & Crop Protection Ltd reported ₹347 Cr of revenue in the Jun 26 quarter, +8.4% year on year. That is the 6th straight quarter of year-on-year growth. Over 10 years it has compounded at 6.7% a year. The last full year, FY26, came in at ₹1,030 Cr. The last four reported quarters add to ₹1,058 Cr.
FY26 revenue came in at ₹1,030 Cr (+14.3% on the year), capping 10 years at 6.7% compound. The latest quarter (Jun 26) printed ₹347 Cr, +8.4% year on year — the 6th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +8.2% growth against the decade's 6.7% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +8.2% over the last 4 quarters against +8.7%/yr over the last 8 — stabilising; TTM profit +43.5% vs +22.5%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Punjab Chemicals & Crop Protection Ltd's operating margin is 12.0% in the Jun 26 quarter, +1.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 3.0% to 15.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 12.0%, +1.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 3.0%–15.0%.
Why the margin moved: operating margin went +1.0 pp year on year while gross margin went +3.5 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Punjab Chemicals & Crop Protection Ltd earned ₹22.0 Cr of net profit in the Jun 26 quarter, +4.8% year on year. It is the 6th consecutive quarter of growth. Full-year FY26 profit was ₹64.0 Cr. The 10-year compound rate is 17.3%. That is 6.3% of the quarter's revenue. The same quarter a year earlier earned ₹21.0 Cr.
Jun 26 profit was ₹22.0 Cr, +4.8% year on year — the 6th consecutive quarter of growth. On the full year, FY26 printed ₹64.0 Cr (+64.1%), and the 10-year compound rate is 17.3%.
Why profit moved: revenue contributed +8.4% and the margin +1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +63.4% vs revenue +8.2%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 90% of Punjab Chemicals & Crop Protection Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹86.0 Cr of operating cash against ₹64.0 Cr of profit. After ₹56.0 Cr of capital spending, ₹30.0 Cr was left as free cash.
FY26: operating cash of ₹86.0 Cr against reported profit of ₹64.0 Cr, leaving free cash of ₹30.0 Cr after ₹56.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 90% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 90%: the cash cycle stretched 81 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 1.7× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Punjab Chemicals & Crop Protection Ltd's cash conversion cycle runs 115 days in FY26, up from 34 days in FY21. Capital spending ran ₹128 Cr over the last 3 years. At FY26 sales of ₹1,030 Cr each day of that cycle holds about ₹2.8 Cr, so roughly ₹325 Cr sits inside the business at any moment.
FY26: debtors at 72 days, inventory at 145 days — roughly 4.8 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 115 days, looser than FY21's 34.
The full loop: cash goes out to suppliers and production on day 0; stock waits 145 days to sell; customers pay about 72 days after that; and suppliers themselves are paid at 102 days — netting out to the 115-day cycle.
In money terms: at FY26 sales of ₹1,030 Cr, each day of the cycle holds about ₹2.8 Cr — so the 115-day loop keeps roughly ₹325 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹128 Cr over the last 3 fiscal years against ₹76.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹19.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Punjab Chemicals & Crop Protection Ltd earns a ROCE of 19% in FY26. That is up from a trough of 5% in FY17. Return on invested capital clears the cost of that capital by +0.8 percentage points, so growth here adds value rather than only size. The wiring behind it is 6.2% net margin on 1.25× asset turns.
FY26 ROCE is 19%, recovered from a FY17 trough of 5% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 6.2% net margin × 1.25× asset turns × 1.95× balance-sheet leverage ≈ 15.1% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 12.8% − 12.0% = a +0.8 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Punjab Chemicals & Crop Protection Ltd carries total debt of ₹154 Cr against shareholder equity of ₹423 Cr as of Mar 26, a debt-to-equity of 0.36. On the annual view that ratio went from 0.41 in FY22 to 0.36 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹154 Cr against shareholder equity of ₹423 Cr — a debt-to-equity of 0.36. On the annual view, debt-to-equity went from 0.41 (FY22) to 0.36 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions added 2.8 points of Punjab Chemicals & Crop Protection Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 5.9% of the company. Domestic institutions moved +0.2 points over the same window, to 0.6%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +2.8 points over 8 quarters to 5.9%; Domestic institutions: +0.2 points over 8 quarters to 0.6%; Promoters: +0.0 points over 8 quarters to 39.2%.
Why the register moved: foreign institutions drove it (+2.8 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Punjab Chemicals & Crop Protection Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Titan Biotech Ltd524717 | 69.3/100Favorable setup78% evidence | ASLEEP | 29.1/35 Revenue 31.8% · PAT 38.7% · OPM change 6.9 pp 83% evidence | 20.2/25 ROCE 22.8% · OPM 19.9% 76% evidence | 6.0/20 P/E 57.8× · PEG — 50% evidence | 14.0/20 RS sector 41.7% · RS bench 39.3% · 1Y 371.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 29.1 + 20.2 + 6 + 14 = 69.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Sharda Cropchem LtdSHARDACROP | 65.3/100Favorable setup97% evidence | ASLEEP | 23.7/35 Revenue 18.5% · PAT 49% · OPM change -5 pp 95% evidence | 18.5/25 ROCE 30.2% · OPM 17% 95% evidence | 19.2/20 P/E 11.8× · PEG 0.26 100% evidence | 3.9/20 RS sector -10.9% · RS bench -13.7% · 1Y -24.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 23.7 + 18.5 + 19.2 + 3.9 = 65.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -10.9% and the one-year return is -24.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 3Punjab Chemicals & Crop Protection Ltdthis pagePUNJABCHEM | 61.8/100Mixed-positive evidence81% evidence | ASLEEP | 22.7/35 Revenue 8.2% · PAT 43.5% · OPM change 1 pp 95% evidence | 18.3/25 ROCE 18.6% · OPM 12% 95% evidence | 12.1/20 P/E 21× · PEG — 50% evidence | 8.7/20 RS sector -6.2% · RS bench -2.6% · 1Y -13.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 22.7 + 18.3 + 12.1 + 8.7 = 61.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Bayer CropScience LtdBAYERCROP | 61.7/100Mixed-positive evidence70% evidence | ASLEEP | 21.4/35 Revenue 3.7% · PAT 21.7% · OPM change 2.1 pp 83% evidence | 19.1/25 ROCE 20.1% · OPM 18.4% 95% evidence | 8.5/20 P/E 387× · PEG — 15% evidence | 12.7/20 RS sector 9.4% · RS bench -10.7% · 1Y -33.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21.4 + 19.1 + 8.5 + 12.7 = 61.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Dharmaj Crop Guard LtdDHARMAJ | 61.1/100Mixed-positive evidence62% evidence | TURNING | 23.8/35 Revenue 19.6% · PAT 56.9% · OPM change 2.7 pp 62% evidence | 12.9/25 ROCE 16.4% · OPM 4.5% 95% evidence | 10.6/20 P/E 16.6× · PEG — 15% evidence | 13.8/20 RS sector 5% · RS bench -2.5% · 1Y -13.2%4 of 10 weeks ahead 70% evidence |
| Exact sum: 23.8 + 12.9 + 10.6 + 13.8 = 61.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Advance Agrolife LtdADVANCE | 56.3/100Thin evidence · provisional56% evidence | TURNING | 21.4/35 Revenue 27% · PAT 37.6% · OPM change 4.3 pp 83% evidence | 14.8/25 ROCE 19.3% · OPM 10.8% 95% evidence | 10.1/20 P/E 22.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —2 of 10 weeks ahead 0% evidence |
| Exact sum: 21.4 + 14.8 + 10.1 + 10 = 56.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7UPL LtdUPL | 54.2/100Mixed-positive evidence90% evidence | ASLEEP | 20.6/35 Revenue 11.2% · PAT 100% · OPM change -1 pp 88% evidence | 9.3/25 ROCE 10.1% · OPM 19% 100% evidence | 12.5/20 P/E 28.3× · PEG 0.5 100% evidence | 11.8/20 RS sector 4.9% · RS bench -12.2% · 1Y -16.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.6 + 9.3 + 12.5 + 11.8 = 54.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8India Pesticides LtdIPL | 54.0/100Mixed-positive evidence81% evidence | TURNING | 20.0/35 Revenue 17% · PAT 10.1% · OPM change -2 pp 95% evidence | 13.6/25 ROCE 16.7% · OPM 14% 95% evidence | 14.1/20 P/E 16.5× · PEG — 50% evidence | 6.3/20 RS sector -11.9% · RS bench -12.1% · 1Y -27.3%4 of 11 weeks ahead 70% evidence |
| Exact sum: 20 + 13.6 + 14.1 + 6.3 = 54 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Jubilant Ingrevia LtdJUBLINGREA | 52.7/100Mixed-positive evidence93% evidence | FADING | 18.2/35 Revenue 11% · PAT 11.2% · OPM change 1 pp 100% evidence | 10.2/25 ROCE 11.4% · OPM 15% 100% evidence | 6.4/20 P/E 36.8× · PEG 2.37 65% evidence | 17.9/20 RS sector 11.8% · RS bench 7.8% · 1Y -5.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 10.2 + 6.4 + 17.9 = 52.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Bharat Rasayan LtdBHARATRAS | 51.6/100Mixed-positive evidence77% evidence | ASLEEP | 17.1/35 Revenue 5.8% · PAT 3.5% · OPM change 4 pp 83% evidence | 16.5/25 ROCE 17.4% · OPM 16% 95% evidence | 14.7/20 P/E 13.3× · PEG — 50% evidence | 3.3/20 RS sector -33.2% · RS bench -34.6% · 1Y -51.5%0 of 11 weeks ahead 70% evidence |
| Exact sum: 17.1 + 16.5 + 14.7 + 3.3 = 51.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Bhagiradha Chemicals & Industries LtdBHAGCHEM | 51.0/100Mixed-positive evidence88% evidence | TURNING | 23.6/35 Revenue 21.7% · PAT 31.1% · OPM change 7.3 pp 65% evidence | 5.8/25 ROCE 4.5% · OPM 12.3% 100% evidence | 2.0/20 P/E 207× · PEG 3.04 100% evidence | 19.6/20 RS sector 22.5% · RS bench 17.9% · 1Y -0.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 23.6 + 5.8 + 2 + 19.6 = 51 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12GSP Crop Science LtdGSPCROP | 50.4/100Thin evidence · provisional59% evidence | TURNING | 16.5/35 Revenue 21.2% · PAT 37.8% · OPM change -4 pp 88% evidence | 14.3/25 ROCE 19% · OPM 9% 100% evidence | 9.6/20 P/E 26.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 3 weeks ahead 0% evidence |
| Exact sum: 16.5 + 14.3 + 9.6 + 10 = 50.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Dhanuka Agritech LtdDHANUKA | 46.6/100Mixed-negative evidence96% evidence | ASLEEP | 8.3/35 Revenue 0.9% · PAT -5.3% · OPM change -2.5 pp 88% evidence | 19.1/25 ROCE 28.3% · OPM 22.5% 100% evidence | 13.0/20 P/E 15.6× · PEG 1.72 100% evidence | 6.2/20 RS sector -12.4% · RS bench -16.2% · 1Y -40.9%4 of 12 weeks ahead 100% evidence |
| Exact sum: 8.3 + 19.1 + 13 + 6.2 = 46.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Sumitomo Chemical India LtdSUMICHEM | 45.4/100Mixed-negative evidence94% evidence | TURNING | 12.1/35 Revenue -3.6% · PAT 3.9% · OPM change 1 pp 100% evidence | 19.0/25 ROCE 22.1% · OPM 22% 100% evidence | 4.0/20 P/E 44.6× · PEG 4 100% evidence | 10.3/20 RS sector -8.2% · RS bench 6% · 1Y -12.8%9 of 10 weeks ahead 70% evidence |
| Exact sum: 12.1 + 19 + 4 + 10.3 = 45.4 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 15Rallis India LtdRALLIS | 45.3/100Mixed-negative evidence91% evidence | ASLEEP | 16.1/35 Revenue 7.3% · PAT -28.4% · OPM change 2.6 pp 95% evidence | 9.3/25 ROCE 12.8% · OPM 15.2% 95% evidence | 11.4/20 P/E 26.7× · PEG 0.89 100% evidence | 8.5/20 RS sector -1.8% · RS bench -20.7% · 1Y -39.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 16.1 + 9.3 + 11.4 + 8.5 = 45.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16NACL Industries LtdNACLIND | 44.9/100Mixed-negative evidence94% evidence | TURNING | 28.1/35 Revenue 11.9% · PAT 100% · OPM change 3 pp 100% evidence | 4.4/25 ROCE 8.1% · OPM 11% 100% evidence | 3.8/20 P/E 171× · PEG 2.02 100% evidence | 8.6/20 RS sector -12.5% · RS bench 3.8% · 1Y -26.9%10 of 10 weeks ahead 70% evidence |
| Exact sum: 28.1 + 4.4 + 3.8 + 8.6 = 44.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Astec Lifesciences LtdASTEC | 44.9/100Mixed-negative evidence63% evidence | ASLEEP | 23.3/35 Revenue 9.4% · PAT 47.7% · OPM change 11.2 pp 71% evidence | 2.6/25 ROCE -5.4% · OPM -0.8% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.0/20 RS sector -3.5% · RS bench -9.3% · 1Y -27.2%7 of 10 weeks ahead 70% evidence |
| Exact sum: 23.3 + 2.6 + 10 + 9 = 44.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Meghmani Organics LtdMOL | 44.3/100Mixed-negative evidence74% evidence | TURNING | 20.6/35 Revenue -7.8% · PAT 100% · OPM change 7 pp 95% evidence | 9.4/25 ROCE 6.7% · OPM 18% 95% evidence | 10.2/20 P/E 21.3× · PEG — 15% evidence | 4.1/20 RS sector -33.7% · RS bench -13.6% · 1Y -42.8%3 of 10 weeks ahead 70% evidence |
| Exact sum: 20.6 + 9.4 + 10.2 + 4.1 = 44.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Insecticides India LtdINSECTICID | 43.8/100Mixed-negative evidence77% evidence | ASLEEP | 11.9/35 Revenue 7% · PAT -1.4% · OPM change -2 pp 83% evidence | 13.0/25 ROCE 15.8% · OPM 6% 95% evidence | 11.7/20 P/E 13.5× · PEG — 50% evidence | 7.2/20 RS sector -8.5% · RS bench -9.5% · 1Y -38.7%7 of 10 weeks ahead 70% evidence |
| Exact sum: 11.9 + 13 + 11.7 + 7.2 = 43.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Excel Industries LtdEXCELINDUS | 43.1/100Mixed-negative evidence70% evidence | TURNING | 14.4/35 Revenue 12% · PAT -11.8% · OPM change 0 pp 83% evidence | 8.6/25 ROCE 6.1% · OPM 8% 95% evidence | 10.9/20 P/E 16.4× · PEG — 15% evidence | 9.2/20 RS sector -4.6% · RS bench -2.6% · 1Y -27.3%2 of 10 weeks ahead 70% evidence |
| Exact sum: 14.4 + 8.6 + 10.9 + 9.2 = 43.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Epigral LtdEPIGRAL | 41.3/100Mixed-negative evidence94% evidence | ASLEEP | 6.5/35 Revenue 4.8% · PAT -37.4% · OPM change -2 pp 100% evidence | 14.3/25 ROCE 15.5% · OPM 25% 100% evidence | 16.5/20 P/E 17.3× · PEG 0.43 100% evidence | 4.0/20 RS sector -32.9% · RS bench -17.5% · 1Y -40.9%7 of 10 weeks ahead 70% evidence |
| Exact sum: 6.5 + 14.3 + 16.5 + 4 = 41.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 22P I Industries LtdPIIND | 40.9/100Mixed-negative evidence90% evidence | ASLEEP | 6.6/35 Revenue -15.9% · PAT -20.5% · OPM change -3 pp 88% evidence | 15.5/25 ROCE 15% · OPM 22% 100% evidence | 10.6/20 P/E 34.7× · PEG 1.71 100% evidence | 8.2/20 RS sector -3.4% · RS bench -15.3% · 1Y -32.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 6.6 + 15.5 + 10.6 + 8.2 = 40.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Best Agrolife LtdBESTAGRO | 29.7/100Adverse evidence81% evidence | TURNING | 7.9/35 Revenue -24.1% · PAT -56.5% · OPM change 8 pp 95% evidence | 9.0/25 ROCE 5.2% · OPM 20% 95% evidence | 7.0/20 P/E 22.9× · PEG — 50% evidence | 5.8/20 RS sector -30.7% · RS bench -8.5% · 1Y -36.9%1 of 11 weeks ahead 70% evidence |
| Exact sum: 7.9 + 9 + 7 + 5.8 = 29.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Heranba Industries LtdHERANBA | 25.7/100Adverse evidence65% evidence | ASLEEP | 11.7/35 Revenue 13.1% · PAT -80% · OPM change -2.7 pp 62% evidence | 1.2/25 ROCE -1.6% · OPM -7% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.8/20 RS sector -22% · RS bench -25.7% · 1Y -51.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.7 + 1.2 + 10 + 2.8 = 25.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Punjab Chemicals & Crop Protection Ltd's share price today?
Punjab Chemicals & Crop Protection Ltd trades at ₹1,144, −17.6% over the past year. The company is valued at ₹1,402 Cr. The stock sits at 40% of its 52-week range of ₹909–₹1,493, +3.3% versus its 200-day average. On the tape, the price is in a downtrend, 26 weeks in. — as of 31 July 2026.
What were Punjab Chemicals & Crop Protection Ltd's latest quarterly results?
Punjab Chemicals & Crop Protection Ltd reported revenue of ₹347 Cr and net profit of ₹22.0 Cr for the Jun 26 quarter. Revenue rose 8.4% and profit rose 4.8% year on year. Earnings per share were ₹18.00. The operating margin was 12.0%, 1.0 pp higher than a year earlier. — as of 31 July 2026.
What is Punjab Chemicals & Crop Protection Ltd's revenue?
Punjab Chemicals & Crop Protection Ltd reported revenue of ₹347 Cr in the Jun 26 quarter, +8.4% year on year. For the full FY26 fiscal year, revenue was ₹1,030 Cr (+14.3%). Over the last 10 years revenue compounded at 6.7% a year. — as of 31 July 2026.
What is Punjab Chemicals & Crop Protection Ltd's profit?
Punjab Chemicals & Crop Protection Ltd earned ₹22.0 Cr of net profit in the Jun 26 quarter, +4.8% year on year — the 6th straight quarter of growth. Full-year FY26 profit was ₹64.0 Cr. The operating margin ran 12.0% in the latest quarter. — as of 31 July 2026.
What is Punjab Chemicals & Crop Protection Ltd's market cap?
Punjab Chemicals & Crop Protection Ltd's market capitalisation is ₹1,402 Cr at a share price of ₹1,144. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Punjab Chemicals & Crop Protection Ltd's P/E ratio?
Punjab Chemicals & Crop Protection Ltd trades at a P/E of 21.0×, at the 21st percentile of its own 10-year range, against a long-run median of 29.3×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Punjab Chemicals & Crop Protection Ltd pay a dividend?
Yes — Punjab Chemicals & Crop Protection Ltd's dividend payout was 6% of profit in FY26, and it recorded a payout in 9 of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Punjab Chemicals & Crop Protection Ltd overvalued?
On its own history, Punjab Chemicals & Crop Protection Ltd looks cheap against its own history: its P/E of 21.0× has been cheaper only 21% of the time in 10 years (long-run median 29.3×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Punjab Chemicals & Crop Protection Ltd growing?
Yes — Punjab Chemicals & Crop Protection Ltd is growing: latest-quarter revenue +8.4% year on year, profit +4.8%, and the margin +1.0 pp at 12.0%. The 10-year compound rates are 6.7% (revenue) and 17.3% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Punjab Chemicals & Crop Protection Ltd performing?
Punjab Chemicals & Crop Protection Ltd is in a downtrend, 26 weeks in. Its latest quarter's revenue rose 8.4% and profit rose 4.8% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Punjab Chemicals & Crop Protection Ltd in?
Improving — profit growth bottomed 7 quarters ago at −39.7% and has held its recovery at +43.5%, ROCE holding at 19.0%. The read comes from the last 12 quarters of growth (revenue growth +8.2% latest, profit growth +43.5% latest, eps growth +41.8% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Punjab Chemicals & Crop Protection Ltd in an uptrend?
No — the price is in a downtrend (week 26 of stage 4), trading +3.3% versus its 200-day average and at 40% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Punjab Chemicals & Crop Protection Ltd beating the market?
On recent form, yes — Punjab Chemicals & Crop Protection Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 4 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +784% against the NIFTY 500's +276% — ahead of the index over the full window. — as of 31 July 2026.
Will Punjab Chemicals & Crop Protection Ltd's share price go up?
This page publishes no price forecast for Punjab Chemicals & Crop Protection Ltd. What it measures instead: the share price is ₹1,144, the price is in a downtrend 26 weeks in. Its P/E of 21.0× sits at the 21st percentile of its own 10-year range. — as of 31 July 2026.
Who owns Punjab Chemicals & Crop Protection Ltd?
Promoters hold 39.2% of Punjab Chemicals & Crop Protection Ltd, foreign institutions 5.9%, domestic institutions 0.6% and the public 54.3% (latest quarter). The biggest move on the register over the last two years: Foreign institutions added 2.8 points over 8 quarters. — as of 31 July 2026.
Does Punjab Chemicals & Crop Protection Ltd have too much debt?
It is moderate — Punjab Chemicals & Crop Protection Ltd's debt-to-equity is 0.36, and operating profit covers the interest bill 7×. FY26 borrowings were ₹154 Cr against equity of ₹423 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is Punjab Chemicals & Crop Protection Ltd's capex?
Punjab Chemicals & Crop Protection Ltd spent ₹128 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹56.0 Cr, with ₹19.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Punjab Chemicals & Crop Protection Ltd's cash flow?
Punjab Chemicals & Crop Protection Ltd generated ₹86.0 Cr of operating cash flow in FY26 and ₹30.0 Cr of free cash flow after ₹56.0 Cr of capital spending. Reported profit that year was ₹64.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Punjab Chemicals & Crop Protection Ltd's profit real cash?
Yes — over the last 3 fiscal years, 90% of Punjab Chemicals & Crop Protection Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹86.0 Cr against reported profit of ₹64.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Punjab Chemicals & Crop Protection Ltd in its business cycle?
Punjab Chemicals & Crop Protection Ltd's FY26 operating margin was 11.0%, against a 13-year band of 3.0%–15.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 12.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Punjab Chemicals & Crop Protection Ltd story?
The sharpest disagreement: annual EPS moved +64.3% against a −17.6% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Punjab Chemicals & Crop Protection Ltd a stock worth studying right now?
This is not investment advice. The machine read: Punjab Chemicals & Crop Protection Ltd's earnings have outrun its stock. EPS grew +64.3% in a year against a −17.6% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.